News

• November 8, 2023
  

  C-Path Partners with Unite4TB to Create a New Dawn in the Fight Against Tuberculosis

  C-Path is proud to be part of UNITE4TB, a public-private partnership funded by the Innovative Medicines Initiative and part of the AMR Accelerator.  A new dawn in the fight against Tuberculosis UNITE4TB, the largest public-private collaboration in tuberculosis drug development, announces start of clinical trials    8 November 2023. Today, UNITE4TB, an international public-private partnership...
• October 30, 2023
  

  eCOA Consortium Announces Publication of an Open Access Article

  C-Path’s eCOA Consortium is pleased to announce the publication of an open access article in Value in Health titled “Best Practices for the Electronic Implementation and Migration of Patient-Reported Outcome Measures.” This article builds upon existing best practices for the electronic migration and implementation of patient-reported outcome measures to provide a comprehensive single point of...
• October 24, 2023
  

  Critical Path for Parkinson’s Welcomes New Co-chairs Pagano, Gaetano

    Critical Path for Parkinson’s mission is to serve as a leading international consortium convening diverse stakeholders to collectively advance data driven collaborative research aimed at accelerating drug development. The CPP co-director has a unique opportunity for broad visibility and to contribute to advancing regulatory science and encourage collaboration amongst all stakeholders. The benefits to...
• September 20, 2023
  

  The CPP Consortium Welcomes Biohaven as its Newest Member

    The Critical Path for Parkinson’s Consortium is excited to welcome Biohaven as its newest member. Biohaven is a biopharmaceutical company aimed at discovering and developing novel life-changing therapies for people living with neurological and neuropsychiatric diseases by collaborating with leaders in scientific discovery and medicine. CPP is excited to work with Biohaven as one of many new members from...
• August 25, 2023
  

  C-Path’s Romero Appears on The BioCentury Show

  Klaus Romero, Chief Science Officer at Critical Path Institute, occupies a rare role in the industry, as the top scientist in an organization whose mission is to solve industry-wide bottlenecks in drug development, with a path that leads directly to endorsement by FDA and other regulatory bodies. On the latest episode of The BioCentury Show, Romero...